Current Report Filing (8-k)
September 15 2020 - 4:21PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 15, 2020
ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
|
001-36435
(Commission File Number)
|
22-2372868
(IRS Employer Identification No.)
|
20 Commerce Drive (Suite 135), Cranford,
New Jersey
(Address of principal executive offices)
|
|
07016
(Zip Code)
|
(732) 980-4500
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of Each Class
|
|
Trading Symbol(s)
|
|
Name of Each Exchange on
Which Registered
|
None
|
|
N/A
|
|
N/A
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01 Other Events
On September 15, 2020,
Enzon Pharmaceuticals, Inc. issued a press release announcing key dates for its proposed $43.6 million rights offering, including
the record date and expected subscription period. A copy of the press release is attached as Exhibit 99.1 to
this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ENZON PHARMACEUTICALS, INC.
|
|
|
(Registrant)
|
|
Date: September 15, 2020
|
|
|
|
|
|
|
|
|
By:
|
/s/ Andrew Rackear
|
|
|
Name: Andrew Rackear
|
|
|
Title: Chief Executive Officer and Secretary
|
|
Enzon (QX) (USOTC:ENZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzon (QX) (USOTC:ENZN)
Historical Stock Chart
From Apr 2023 to Apr 2024